MOUNTAIN VIEW, Calif., Jan. 30 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. today announced that the company will present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference on Wednesday, February 6, 2008, at 1:40 pm (ET) in New York City.
A live webcast of the presentation will be available on the Investor Relations section of MAP Pharmaceuticals' website at http://www.mappharma.com. A replay will also be available within 24 hours for seven days following the presentation.
About MAP Pharmaceuticals, Inc.
MAP Pharmaceuticals develops and plans to commercialize new therapies for children and adults who suffer from diseases that the company believes are not treated adequately by currently available medicines. The company uses proprietary inhalation technologies to enhance the therapeutic benefits and commercial attractiveness of proven drugs, while minimizing risk by capitalizing on their known safety, efficacy and commercialization history. The company has several product candidates in clinical development that address large market opportunities, including its two most advanced product candidates: UDB, a proprietary version of nebulized budesonide for the potential treatment of children with asthma; and MAP0004, a proprietary version of orally inhaled dihydroergotamine delivered by MAP Pharmaceuticals' Tempo(TM) inhaler for the potential treatment of migraine. The company is also developing a proprietary combination of an inhaled corticosteroid with a long-acting beta2-agonist for the potential treatment of asthma and chronic obstructive pulmonary disease.
Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.
CONTACT: Lisa Johnson of MAP Pharmaceuticals, Inc., +1-650-386-3122,
ljohnson@mappharma.com
Web site: http://www.mappharma.com/
